Mostrar registro simples

dc.contributor.authorBastos, Catherina Isdra Moszkowiczpt_BR
dc.contributor.authorDani, Carolinept_BR
dc.contributor.authorCechinel, Laura Reckpt_BR
dc.contributor.authorNeves, Arthur Hipolito da Silvapt_BR
dc.contributor.authorRasia, Fabiana Briatopt_BR
dc.contributor.authorLamers, Marcelo Lazzaronpt_BR
dc.contributor.authorBianchi, Sara Elispt_BR
dc.contributor.authorMeirelles, Gabriela de Carvalhopt_BR
dc.contributor.authorWorm, Paulo Valdecipt_BR
dc.contributor.authorBassani, Valquiria Linckpt_BR
dc.contributor.authorSiqueira, Ionara Rodriguespt_BR
dc.date.accessioned2025-10-01T07:54:08Zpt_BR
dc.date.issued2025pt_BR
dc.identifier.issn1424-8247pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/297596pt_BR
dc.description.abstractThe need for the scientific validation of traditional and folk medicine knowledge has emerged lately. Achyrocline satureioides inflorescences have been widely used for the management of mild viral respiratory infection symptoms in South Brazil, Uruguay and Argentina. We intended to assess the therapeutic efficacy of a 14-day course with A. satureioides for mild viral respiratory infection symptoms. Methods: We conducted a randomized, open-label, placebo-controlled trial. Before COVID-19 (SARSCoV- 2) diagnostic tests, participants were randomly assigned to one of two experimental groups: A. satureioides or Malus domestica infusions, with instructions to use the infusions twice a day for 14 days. Our primary endpoint was the recovery time for respiratory symptoms in the overall analysis; the secondary outcomes were the recovery time for non-respiratory symptoms and for stratified analysis, taking into account the vaccination status against SARS-CoV-2 and COVID-19 infection; and the rate of symptom recovery was also evaluated. Results: The A. satureioides infusion significantly accelerated the resolution of sore throat and sneezing compared with the control group. The participants with COVID-19 who had not been vaccinated and received A. satureioides infusion recovered faster from sore throat, body ache, fever and cough, and showed a shorter median survival time for symptom resolution. The SARS-CoV-2-negative group that received A. satureioides had a faster improvement in the survival analysis of sore throat, earache and loss of appetite. Conclusions: Our findings support the hypothesis that Achyrocline satureioides inflorescence infusions may offer therapeutic benefits in the management of mild viral respiratory infections, as its administration was associated with a significantly accelerated resolution of clinical symptoms.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofPharmaceuticals. Basel. Vol. 18, no. 6 (June 2025), 861, 16 p.pt_BR
dc.rightsOpen Accessen
dc.subjectCoronaviruspt_BR
dc.subjectColden
dc.subjectFluen
dc.subjectAchyroclinept_BR
dc.subjectMacelapt_BR
dc.subjectHerbal medicineen
dc.subjectMedicinal planten
dc.subjectCOVID-19pt_BR
dc.titleValidation of a traditional medicine, Achyrocline satureioides infusion, for the improvement of mild respiratory infection symptoms : a randomized, placebo-controlled and open-label clinical trialpt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001294035pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples